Warde Medical Laboratory

LABORATORY REPORT

QC ACCOUNT (WARDE)
300 W. TEXTILE
ANN ARBOR MI 48108

EXAMPLE, REPORT
WX0000000237 F 12/05/1988 36 Y

Referral Testing

Collected: 09/18/2025 09:40 Received: 09/18/2025 09:40

Test Name	Result	Flag	Ref-Ranges	Units	Site

JAK2 Exon 12-Mutation Analysis by PCR

JAK2EX12, Source	Whole Blood		ARRL
JAK2EX12, Interpretation	Not Detected		ARRL

There is no evidence of a JAK2 Exon 12 mutation. This result does not exclude the possibility of a JAK2 Exon 12 mutation below the test limit of detection or one which is not detectable by the assay specific design.

This result has been reviewed and approved by Archana Agarwal, M.D.
INTERPRETIVE INFORMATION: JAK2 Exon 12-Mutation Analysis by PCR
DNA from whole blood or bone marrow is isolated and subjected to PCR amplification in the presence of a short blocking oligonucleotide homologous to codons 537-544 of exon 12 of the wild-type JAK2 gene. The oligonucleotide is designed to specifically suppress PCR amplification of wild-type JAK2 exon 12 sequence. In contrast, JAK2 exon 12 mutations located between codons 537-544 disrupt proper binding of the blocking oligonucleotide during PCR amplification resulting in a product of approximately 225 base-pairs. Each assay includes control DNA from mutation positive and wild-type negative samples; all samples are tested in paired reactions with and without blocking oligonucleotide. A PCR product formed in the presence of blocking oligonucleotide indicates the presence of a mutation.

Results of this test must always be interpreted in the context of clinical and other relevant laboratory data such as erythropoietin level, exclusion of other causes of elevated hemoglobin, and should not be used alone for a diagnosis of polycythemia vera which is a form of malignancy, i.e, myeloproliferative disorder. This test does not identify JAK2 mutation outside of codons 537-544, and duplications or missense variants that compromise oligonucleotide binding may not be detected.

Limit of Detection: 5 percent mutant alleles for length-altering mutations.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Warde Medical Laboratory

LABORATORY REPORT

QC ACCOUNT (WARDE)
300 W. TEXTILE
ANN ARBOR MI 48108

EXAMPLE, REPORT
WX0000000237 F 12/05/1988 36 Y

Referral Testing

Collected: 09/18/2025 09:40 Received: 09/18/2025 09:40

Test Name	Result	Flag	Ref-Ranges	Units	Site

Performed By: ARUP Laboratories
500 Chipeta Way
Salt Lake City, UT 84108
Laboratory Director: Jonathan R. Genzen, MD, PhD
CLIA Number: 46D0523979

Reported Date: 09/18/2025 09:40 JAK2E

Performing Site:
ARRL: ARUP REFERENCE LAB 500 Chipeta Way Salt Lake City UT 841081221

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

E118000009
WX0000000237
Printed D&T: 09/18/25 09:41

Ordered By: CLIENT CLIENT
WX00000000000336

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1